7 news items
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
VANI
13 May 24
continues advancing the development of miniature, long-term GLP-1 implants for the treatment of chronic weight management in obese or overweight patients
Vivani Medical to Present at TIDES Conference 2024
VANI
9 May 24
) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
VANI
26 Mar 24
shift prioritizes the development of GLP-1 implants for the treatment of obesity and chronic weight management
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
VANI
6 Mar 24
the development of its GLP-1 implants for the treatment of obesity and chronic weight management
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
VANI
1 Mar 24
medication tolerability. Vivani's NPM-115 and NPM-119 are miniature, six-month, GLP-1 implants in development for the treatment of chronic weight management
c4to8u8ou0qb1z38 2u0w9z
VANI
28 Feb 24
NPM-115 and NPM-139 are miniature, subdermal implants in development for chronic weight management designed
wqcul6gxn2uqg961i3mwtqs4jfpepkczsz qf87o
AZN
NVO
VANI
28 Feb 24
for chronic weight management.
In a study in high-fat diet-induced obese mice, NPM-115 generated weight loss of approximately 20
- Prev
- 1
- Next